APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Inhalable Biologics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Respiratory Inhalable Biologics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17392115038 January 2026195 pages

Choose your research edition.

Industry ResearchRespiratory Inhalable Biologics Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Inhalable Biologics Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Respiratory Inhalable Biologics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Inhalable Biologics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Inhalable Biologics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Respiratory Inhalable Biologics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Respiratory Inhalable Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Respiratory Inhalable Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Inhalable Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Respiratory Inhalable Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Respiratory Inhalable Biologics include GSK, AstraZeneca, Boehringer Ingelheim, Vertex, Roche, Novartis, Chiesi, Teva and Prasco Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Respiratory Inhalable Biologics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Respiratory Inhalable Biologics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Respiratory Inhalable Biologics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Respiratory Inhalable Biologics market size, projected growth trends, production technologies, key applications, and end-use industries.

Respiratory Inhalable Biologics Segment by Company

GSK

AstraZeneca

Boehringer Ingelheim

Vertex

Roche

Novartis

Chiesi

Teva

Prasco Laboratories

Viatris

Amgen

Sumitomo Dainippon

Zhengdatianqing

Merck

Respiratory Inhalable Biologics Segment by Type

Protein Drugs

Peptide Drugs

Monoclonal Antibodies

Others

Respiratory Inhalable Biologics Segment by Application

Hospital

Retail Pharmacy

Others

Respiratory Inhalable Biologics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Inhalable Biologics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Inhalable Biologics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Inhalable Biologics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Inhalable Biologics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Respiratory Inhalable Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Respiratory Inhalable Biologics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Respiratory Inhalable Biologics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Respiratory Inhalable Biologics Industry Trends Table 2. Respiratory Inhalable Biologics Industry Drivers Table 3. Respiratory Inhalable Biologics Industry Opportunities and Challenges Table 4. Respiratory Inhalable Biologics Industry Restraints Table 5. Global Respiratory Inhalable Biologics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Respiratory Inhalable Biologics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Respiratory Inhalable Biologics Sales by Manufacturers (k units ) & (2021-2026) Table 8. Global Respiratory Inhalable Biologics Sales Market Share by Manufacturers Table 9. Global Respiratory Inhalable Biologics Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Respiratory Inhalable Biologics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Respiratory Inhalable Biologics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Respiratory Inhalable Biologics Manufacturers, Product Type & Application Table 13. Global Respiratory Inhalable Biologics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Respiratory Inhalable Biologics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Protein Drugs Table 17. Major Manufacturers of Peptide Drugs Table 18. Major Manufacturers of Monoclonal Antibodies Table 19. Major Manufacturers of Others Table 20. Global Respiratory Inhalable Biologics Sales by Type 2021 VS 2025 VS 2032 (k units ) Table 21. Global Respiratory Inhalable Biologics Sales by Type (2021-2026) & (k units ) Table 22. Global Respiratory Inhalable Biologics Sales by Type (2027-2032) & (k units ) Table 23. Global Respiratory Inhalable Biologics Sales Market Share by Type (2021-2026) Table 24. Global Respiratory Inhalable Biologics Sales Market Share by Type (2027-2032) Table 25. Global Respiratory Inhalable Biologics Revenue by Type 2021 VS 2025 VS 2032 (k units ) Table 26. Global Respiratory Inhalable Biologics Revenue by Type (2021-2026) & (k units ) Table 27. Global Respiratory Inhalable Biologics Revenue by Type (2027-2032) & (k units ) Table 28. Global Respiratory Inhalable Biologics Revenue Market Share by Type (2021-2026) Table 29. Global Respiratory Inhalable Biologics Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Retail Pharmacy Table 32. Major Manufacturers of Others Table 33. Global Respiratory Inhalable Biologics Sales by Application 2021 VS 2025 VS 2032 (k units ) Table 34. Global Respiratory Inhalable Biologics Sales by Application (2021-2026) & (k units ) Table 35. Global Respiratory Inhalable Biologics Sales by Application (2027-2032) & (k units ) Table 36. Global Respiratory Inhalable Biologics Sales Market Share by Application (2021-2026) Table 37. Global Respiratory Inhalable Biologics Sales Market Share by Application (2027-2032) Table 38. Global Respiratory Inhalable Biologics Revenue by Application 2021 VS 2025 VS 2032 (k units ) Table 39. Global Respiratory Inhalable Biologics Revenue by Application (2021-2026) & (k units ) Table 40. Global Respiratory Inhalable Biologics Revenue by Application (2027-2032) & (k units ) Table 41. Global Respiratory Inhalable Biologics Revenue Market Share by Application (2021-2026) Table 42. Global Respiratory Inhalable Biologics Revenue Market Share by Application (2027-2032) Table 43. Global Respiratory Inhalable Biologics Sales by Region: 2021 VS 2025 VS 2032 (k units ) Table 44. Global Respiratory Inhalable Biologics Sales by Region (2021-2026) & (k units ) Table 45. Global Respiratory Inhalable Biologics Sales Market Share by Region (2021-2026) Table 46. Global Respiratory Inhalable Biologics Sales Forecasted by Region (2027-2032) & (k units ) Table 47. Global Respiratory Inhalable Biologics Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Respiratory Inhalable Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units ) Table 49. North America Respiratory Inhalable Biologics Sales by Country (2021-2026) & (k units ) Table 50. North America Respiratory Inhalable Biologics Sales by Country (2027-2032) & (k units ) Table 51. Europe Respiratory Inhalable Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units ) Table 52. Europe Respiratory Inhalable Biologics Sales by Country (2021-2026) & (k units ) Table 53. Europe Respiratory Inhalable Biologics Sales by Country (2027-2032) & (k units ) Table 54. Asia Pacific Respiratory Inhalable Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units ) Table 55. Asia Pacific Respiratory Inhalable Biologics Sales by Country (2021-2026) & (k units ) Table 56. Asia Pacific Respiratory Inhalable Biologics Sales by Country (2027-2032) & (k units ) Table 57. South America, Middle East and Africa Respiratory Inhalable Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units ) Table 58. South America, Middle East and Africa Respiratory Inhalable Biologics Sales by Country (2021-2026) & (k units ) Table 59. South America, Middle East and Africa Respiratory Inhalable Biologics Sales by Country (2027-2032) & (k units ) Table 60. Global Respiratory Inhalable Biologics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Respiratory Inhalable Biologics Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Respiratory Inhalable Biologics Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Respiratory Inhalable Biologics Revenue Market Share by Region (2021-2026) Table 64. Global Respiratory Inhalable Biologics Revenue Market Share by Region (2027-2032) Table 65. GSK Company Information Table 66. GSK Business Overview Table 67. GSK Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. GSK Respiratory Inhalable Biologics Product Portfolio Table 69. GSK Recent Development Table 70. AstraZeneca Company Information Table 71. AstraZeneca Business Overview Table 72. AstraZeneca Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. AstraZeneca Respiratory Inhalable Biologics Product Portfolio Table 74. AstraZeneca Recent Development Table 75. Boehringer Ingelheim Company Information Table 76. Boehringer Ingelheim Business Overview Table 77. Boehringer Ingelheim Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Boehringer Ingelheim Respiratory Inhalable Biologics Product Portfolio Table 79. Boehringer Ingelheim Recent Development Table 80. Vertex Company Information Table 81. Vertex Business Overview Table 82. Vertex Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Vertex Respiratory Inhalable Biologics Product Portfolio Table 84. Vertex Recent Development Table 85. Roche Company Information Table 86. Roche Business Overview Table 87. Roche Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Roche Respiratory Inhalable Biologics Product Portfolio Table 89. Roche Recent Development Table 90. Novartis Company Information Table 91. Novartis Business Overview Table 92. Novartis Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Novartis Respiratory Inhalable Biologics Product Portfolio Table 94. Novartis Recent Development Table 95. Chiesi Company Information Table 96. Chiesi Business Overview Table 97. Chiesi Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Chiesi Respiratory Inhalable Biologics Product Portfolio Table 99. Chiesi Recent Development Table 100. Teva Company Information Table 101. Teva Business Overview Table 102. Teva Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Teva Respiratory Inhalable Biologics Product Portfolio Table 104. Teva Recent Development Table 105. Prasco Laboratories Company Information Table 106. Prasco Laboratories Business Overview Table 107. Prasco Laboratories Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Prasco Laboratories Respiratory Inhalable Biologics Product Portfolio Table 109. Prasco Laboratories Recent Development Table 110. Viatris Company Information Table 111. Viatris Business Overview Table 112. Viatris Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Viatris Respiratory Inhalable Biologics Product Portfolio Table 114. Viatris Recent Development Table 115. Amgen Company Information Table 116. Amgen Business Overview Table 117. Amgen Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Amgen Respiratory Inhalable Biologics Product Portfolio Table 119. Amgen Recent Development Table 120. Sumitomo Dainippon Company Information Table 121. Sumitomo Dainippon Business Overview Table 122. Sumitomo Dainippon Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Sumitomo Dainippon Respiratory Inhalable Biologics Product Portfolio Table 124. Sumitomo Dainippon Recent Development Table 125. Zhengdatianqing Company Information Table 126. Zhengdatianqing Business Overview Table 127. Zhengdatianqing Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Zhengdatianqing Respiratory Inhalable Biologics Product Portfolio Table 129. Zhengdatianqing Recent Development Table 130. Merck Company Information Table 131. Merck Business Overview Table 132. Merck Respiratory Inhalable Biologics Sales (k units ), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Merck Respiratory Inhalable Biologics Product Portfolio Table 134. Merck Recent Development Table 135. Key Raw Materials Table 136. Raw Materials Key Suppliers Table 137. Respiratory Inhalable Biologics Distributors List Table 138. Respiratory Inhalable Biologics Customers List Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Respiratory Inhalable Biologics Product Image Figure 2. Global Respiratory Inhalable Biologics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Inhalable Biologics Market Size (2021-2032) & (US$ Million) Figure 4. Global Respiratory Inhalable Biologics Sales (2021-2032) & (k units ) Figure 5. Global Respiratory Inhalable Biologics Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Respiratory Inhalable Biologics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Protein Drugs Image Figure 9. Peptide Drugs Image Figure 10. Monoclonal Antibodies Image Figure 11. Others Image Figure 12. Global Respiratory Inhalable Biologics Sales by Type (2021 VS 2025 VS 2032) & (k units ) Figure 13. Global Respiratory Inhalable Biologics Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Respiratory Inhalable Biologics Sales Market Share by Type (2021-2032) Figure 15. Global Respiratory Inhalable Biologics Revenue by Type (2021 VS 2025 VS 2032) & (k units ) Figure 16. Global Respiratory Inhalable Biologics Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Respiratory Inhalable Biologics Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Retail Pharmacy Image Figure 20. Others Image Figure 21. Global Respiratory Inhalable Biologics Sales by Application (2021 VS 2025 VS 2032) & (k units ) Figure 22. Global Respiratory Inhalable Biologics Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Respiratory Inhalable Biologics Sales Market Share by Application (2021-2032) Figure 24. Global Respiratory Inhalable Biologics Revenue by Application (2021 VS 2025 VS 2032) & (k units ) Figure 25. Global Respiratory Inhalable Biologics Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Respiratory Inhalable Biologics Revenue Market Share by Application (2021-2032) Figure 27. North America Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 28. North America Respiratory Inhalable Biologics Sales Market Share by Country (2021-2032) Figure 29. U.S. Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 30. Canada Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 31. Mexico Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 32. Europe Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 33. Europe Respiratory Inhalable Biologics Sales Market Share by Country (2021-2032) Figure 34. Germany Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 35. France Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 36. U.K. Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 37. Italy Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 38. Netherlands Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 39. Asia Pacific Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 40. Asia Pacific Respiratory Inhalable Biologics Sales Market Share by Country (2021-2032) Figure 41. China Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 42. Japan Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 43. South Korea Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 44. Southeast Asia Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 45. India Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 46. Australia Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 47. South America, Middle East and Africa Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 48. South America, Middle East and Africa Respiratory Inhalable Biologics Sales Market Share by Country (2021-2032) Figure 49. Brazil Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 50. South Africa Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 51. Saudi Arabia Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 52. Turkey Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 53. Argentina Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 54. UAE Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 55. Egypt Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 56. Chile Respiratory Inhalable Biologics Sales and Growth Rate (2021-2032) & (k units ) Figure 57. Global Respiratory Inhalable Biologics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Respiratory Inhalable Biologics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Figure 60. North America Respiratory Inhalable Biologics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Figure 62. Europe Respiratory Inhalable Biologics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Respiratory Inhalable Biologics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Respiratory Inhalable Biologics Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Respiratory Inhalable Biologics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Respiratory Inhalable Biologics Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Respiratory Inhalable Biologics Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Protein Drugs
  • Peptide Drugs
  • Monoclonal Antibodies
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Others
Companies covered
  • GSK
  • AstraZeneca
  • Boehringer Ingelheim
  • Vertex
  • Roche
  • Novartis
  • Chiesi
  • Teva
  • Prasco Laboratories
  • Viatris
  • Amgen
  • Sumitomo Dainippon
  • Zhengdatianqing
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Respiratory Inhalable Biologics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Respiratory Inhalable Biologics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Respiratory Inhalable Biologics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Respiratory Inhalable Biologics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Respiratory Inhalable Biologics Market Dynamics
  1. 2.1 Respiratory Inhalable Biologics Industry Trends
  2. 2.2 Respiratory Inhalable Biologics Industry Drivers
  3. 2.3 Respiratory Inhalable Biologics Industry Opportunities and Challenges
  4. 2.4 Respiratory Inhalable Biologics Industry Restraints
3 Respiratory Inhalable Biologics Market by Manufacturers
  1. 3.1 Global Respiratory Inhalable Biologics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Respiratory Inhalable Biologics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Respiratory Inhalable Biologics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Respiratory Inhalable Biologics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Respiratory Inhalable Biologics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Respiratory Inhalable Biologics Manufacturers, Product Type & Application
  7. 3.7 Global Respiratory Inhalable Biologics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Respiratory Inhalable Biologics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Respiratory Inhalable Biologics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Respiratory Inhalable Biologics Tier 1, Tier 2, and Tier 3
4 Respiratory Inhalable Biologics Market by Type
  1. 4.1 Respiratory Inhalable Biologics Type Introduction
  2. 4.1.1 Protein Drugs
  3. 4.1.2 Peptide Drugs
  4. 4.1.3 Monoclonal Antibodies
  5. 4.1.4 Others
  6. 4.2 Global Respiratory Inhalable Biologics Sales by Type
  7. 4.2.1 Global Respiratory Inhalable Biologics Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Respiratory Inhalable Biologics Sales by Type (2021-2032)
  9. 4.2.3 Global Respiratory Inhalable Biologics Sales Market Share by Type (2021-2032)
  10. 4.3 Global Respiratory Inhalable Biologics Revenue by Type
  11. 4.3.1 Global Respiratory Inhalable Biologics Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Respiratory Inhalable Biologics Revenue by Type (2021-2032)
  13. 4.3.3 Global Respiratory Inhalable Biologics Revenue Market Share by Type (2021-2032)
5 Respiratory Inhalable Biologics Market by Application
  1. 5.1 Respiratory Inhalable Biologics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Others
  5. 5.2 Global Respiratory Inhalable Biologics Sales by Application
  6. 5.2.1 Global Respiratory Inhalable Biologics Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Inhalable Biologics Sales by Application (2021-2032)
  8. 5.2.3 Global Respiratory Inhalable Biologics Sales Market Share by Application (2021-2032)
  9. 5.3 Global Respiratory Inhalable Biologics Revenue by Application
  10. 5.3.1 Global Respiratory Inhalable Biologics Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Respiratory Inhalable Biologics Revenue by Application (2021-2032)
  12. 5.3.3 Global Respiratory Inhalable Biologics Revenue Market Share by Application (2021-2032)
6 Global Respiratory Inhalable Biologics Sales by Region
  1. 6.1 Global Respiratory Inhalable Biologics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Respiratory Inhalable Biologics Sales by Region (2021-2032)
  3. 6.2.1 Global Respiratory Inhalable Biologics Sales by Region (2021-2026)
  4. 6.2.2 Global Respiratory Inhalable Biologics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Respiratory Inhalable Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Respiratory Inhalable Biologics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Respiratory Inhalable Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Respiratory Inhalable Biologics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Respiratory Inhalable Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Respiratory Inhalable Biologics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Respiratory Inhalable Biologics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Respiratory Inhalable Biologics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Respiratory Inhalable Biologics Revenue by Region
  1. 7.1 Global Respiratory Inhalable Biologics Revenue by Region
  2. 7.1.1 Global Respiratory Inhalable Biologics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Respiratory Inhalable Biologics Revenue by Region (2021-2026)
  4. 7.1.3 Global Respiratory Inhalable Biologics Revenue by Region (2027-2032)
  5. 7.1.4 Global Respiratory Inhalable Biologics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Respiratory Inhalable Biologics Revenue (2021-2032)
  8. 7.2.2 North America Respiratory Inhalable Biologics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Respiratory Inhalable Biologics Revenue (2021-2032)
  11. 7.3.2 Europe Respiratory Inhalable Biologics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Respiratory Inhalable Biologics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Respiratory Inhalable Biologics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Respiratory Inhalable Biologics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Respiratory Inhalable Biologics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Respiratory Inhalable Biologics Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Respiratory Inhalable Biologics Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Respiratory Inhalable Biologics Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Vertex
  20. 8.4.1 Vertex Company Information
  21. 8.4.2 Vertex Business Overview
  22. 8.4.3 Vertex Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vertex Respiratory Inhalable Biologics Product Portfolio
  24. 8.4.5 Vertex Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Respiratory Inhalable Biologics Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Respiratory Inhalable Biologics Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Chiesi
  38. 8.7.1 Chiesi Company Information
  39. 8.7.2 Chiesi Business Overview
  40. 8.7.3 Chiesi Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Chiesi Respiratory Inhalable Biologics Product Portfolio
  42. 8.7.5 Chiesi Recent Developments
  43. 8.8 Teva
  44. 8.8.1 Teva Company Information
  45. 8.8.2 Teva Business Overview
  46. 8.8.3 Teva Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Teva Respiratory Inhalable Biologics Product Portfolio
  48. 8.8.5 Teva Recent Developments
  49. 8.9 Prasco Laboratories
  50. 8.9.1 Prasco Laboratories Company Information
  51. 8.9.2 Prasco Laboratories Business Overview
  52. 8.9.3 Prasco Laboratories Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Prasco Laboratories Respiratory Inhalable Biologics Product Portfolio
  54. 8.9.5 Prasco Laboratories Recent Developments
  55. 8.10 Viatris
  56. 8.10.1 Viatris Company Information
  57. 8.10.2 Viatris Business Overview
  58. 8.10.3 Viatris Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Viatris Respiratory Inhalable Biologics Product Portfolio
  60. 8.10.5 Viatris Recent Developments
  61. 8.11 Amgen
  62. 8.11.1 Amgen Company Information
  63. 8.11.2 Amgen Business Overview
  64. 8.11.3 Amgen Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Respiratory Inhalable Biologics Product Portfolio
  66. 8.11.5 Amgen Recent Developments
  67. 8.12 Sumitomo Dainippon
  68. 8.12.1 Sumitomo Dainippon Company Information
  69. 8.12.2 Sumitomo Dainippon Business Overview
  70. 8.12.3 Sumitomo Dainippon Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sumitomo Dainippon Respiratory Inhalable Biologics Product Portfolio
  72. 8.12.5 Sumitomo Dainippon Recent Developments
  73. 8.13 Zhengdatianqing
  74. 8.13.1 Zhengdatianqing Company Information
  75. 8.13.2 Zhengdatianqing Business Overview
  76. 8.13.3 Zhengdatianqing Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Zhengdatianqing Respiratory Inhalable Biologics Product Portfolio
  78. 8.13.5 Zhengdatianqing Recent Developments
  79. 8.14 Merck
  80. 8.14.1 Merck Company Information
  81. 8.14.2 Merck Business Overview
  82. 8.14.3 Merck Respiratory Inhalable Biologics Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Merck Respiratory Inhalable Biologics Product Portfolio
  84. 8.14.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Respiratory Inhalable Biologics Value Chain Analysis
  2. 9.1.1 Respiratory Inhalable Biologics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Respiratory Inhalable Biologics Production Mode & Process
  6. 9.2 Respiratory Inhalable Biologics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Respiratory Inhalable Biologics Distributors
  9. 9.2.3 Respiratory Inhalable Biologics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst